Dr. Reddy's plaque psoriasis treatment secures US approval
Insight Weekly: Loan delinquencies up; US money supply falls; coal employment grows
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
The U.S. Food and Drug Administration approved Dr. Reddy's Laboratories Ltd.'s new drug application for Impoyz cream for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older.
Impoyz is licensed to Encore Dermatology Inc. for commercialization of the product in the U.S.
